$JAZZ

Jazz Pharmaceuticals (JAZZ) reported updated results from the Phase 3 HERIZON-GEA-01 trial, showing Ziihera® (zanidatamab-hrii) combinations improved overall survival in HER2+ advanced gastroesophageal adenocarcinoma. Key findings: 39.8% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, median OS of 27.0 months. Ziihera plus chemotherapy reduced death risk by 24% vs. trastuzumab. Results presented at ESMO 2026.

Jazz Pharmaceuticals' Ziihera (zanidatamab) plus chemotherapy showed improved overall survival in HER2+ advanced gastroesophageal adenocarcinoma (GEA) patients. Median OS reached 27.0 months with Ziihera plus tislelizumab and chemotherapy, reducing death risk by 35%. Nearly 40% of patients were alive at three years. Ziihera plus chemotherapy alone also showed a 24% reduction in death risk. The results were presented at a medical conference.

Jazz Pharmaceuticals announced that Samantha Pearce, its Executive Vice President and Chief Commercial Officer, will retire. Her departure is effective upon the appointment of a successor or by June 30, 2027, according to the company. The board will consider both internal and external candidates for the role.

Jazz Pharmaceuticals plc (JAZZ) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “

Jazz Pharmaceuticals director Anne O’Riordan plans to sell 14,687 shares worth $3.36M on October 8, 2026, and 1,692 shares for $435,673.08 on August 7, 2026, according to a Rule 144 notice. The shares were acquired through stock option exercises, with Morgan Stanley Smith Barney LLC as the broker.

COZADD BRUCE C sold 6,000 shares of Jazz Pharmaceuticals plc (JAZZ) at $230.33 ($1.38M total) on 2026-10-01 under a Rule 10b5-1 trading plan.

Citigroup initiated coverage on Nuvation Bio (NUVB) and Jazz Pharmaceuticals (JAZZ) with Buy ratings. NUVB received a $12 price target, citing strong sales of Ibtrozi and potential of safusidenib. JAZZ was given a $320 target, highlighting Ziihera's growth potential. Both stocks are seen as covered call opportunities.

Analysts made several calls: UBS kept Apple neutral citing stable iPhone wait times. Wells Fargo upgraded Pinnacle Financial and downgraded Ally Financial. Deutsche Bank initiated FormFactor as buy. William Blair initiated CoreWeave and Nebius Group as outperform. Bank of America reiterated Nvidia, Intel, Marvell, Micron, and Lam Research as buy. Citi initiated Nuvation Bio as buy and downgraded Moderna to sell. HSBC upgraded Target to buy. Morgan Stanley reiterated Tesla as equal weight.

Citigroup initiated coverage of Jazz Pharmaceuticals with a 'Buy' rating and a $325 price target. The stock is currently trading at $232.35, down 2.49% over five days and 3.42% year-to-date, but up 36.68% over a longer period. The rating is based on a weighted average of various composite ratings.

Analysts made several rating changes and price target adjustments. JPMorgan upgraded CoreWeave, Welltower, and Macerich, while Citi downgraded Dropbox. Bernstein upgraded Quanta Services, and Morgan Stanley initiated Imax and Nvidia with overweight ratings. Other notable moves include upgrades for Arcturus Therapeutics, Dollar General, and The Brink's Company, and initiations for NeOnc Technologies, Energy Services of America, BayCom, Avidbank, and SpaceX.